10,11-Dehydrocurvularin attenuates inflammation by suppressing NLRP3 inflammasome activation / 中国天然药物

10,11-Dehydrocurvularin (DCV) is a natural-product macrolide that has been shown to exert anti-inflammatory activity. However, the underlying mechanism of its anti-inflammatory activity remains poorly understood. Aberrant activation of the NLRP3 inflammasome is involved in diverse inflammation-related diseases, which should be controlled. The results showed that DCV specifically inhibited the activation of the NLRP3 inflammasome in association with reduced IL-1β secretion and caspase-1 activation, without effect on the NLRC4 and AIM2 inflammasomes. Furthermore, DCV disturbed the interaction between NEK7 and NLRP3, resulting in the inhibition of NLRP3 inflammasome activation. The C=C double bond of DCV was required for the NLRP3 inflammasome inhibition induced by DCV. Importantly, DCV ameliorated inflammation in vivo through inhibiting the NLRP3 inflammasome. Taken together, our study reveals a novel mechanism by which DCV suppresses inflammation, which indicates the potential role of DCV in NLRP3 inflammasome-driven inflammatory disorders.

Influencing factors for early recurrence after curative pancreaticoduodenectomy of pancreatic head cancer / 中华消化外科杂志

Objective:To investigate the influencing factors for early recurrence after curative pancreaticoduodenectomy of pancreatic head cancer.Methods:The retrospective case-control study was conducted. The clinicopathological data of 104 patients with pancreatic head cancer who underwent radical resection in Fudan University Shanghai Cancer Center from May 2014 to May 2015 were collected. There were 62 males and 42 females, aged (61±10)years. Patients underwent carative pancreaticoduodenectomy. Observation indicators: (1) surgical situations; (2) follow-up; (3) influencing factors for early recurrence after curative pancreaticoduodenectomy of pancreatic head cancer. Follow-up was conducted using telephone interview to detect recurrence of patients up to postoperative 1 year. Measurement data with normal distribution were represented as Mean±SD. Count data were described as absolutes numbers, and comparison between groups was analyzed using the chi-square test. Multivariate analysis was analyzed using the Logistic regression model. Results:(1) Surgical situations: 104 patients underwent curative pancreaticoduodenec-tomy successfully. The volume of intraoperative blood loss was (474±280)mL and the number of lymph node dissection was 21±10. (2) Follow-up: 104 patients received postoperative follow-up, 44 of whom had early recurrence. Of the 44 patients with early recurrence, 42 cases had intraperitoneal recurrence including 23 cases with liver metastasis, 7 cases with metastasis in surgical site, 7 cases with retroperitoneal lymph node metastasis, 5 cases with omentum metastasis, 2 cases had extraperitoneal recurrence including 1 case with pleural metastasis and 1 case with pulmonary metastasis. (3) Influencing factors for early recurrence after curative pancreaticoduodenectomy of pancreatic head cancer: results of univariate analysis showed levels of preoperative CA19-9, levels of postoperative CA19-9, the number of lymph node dissection were related factors for early recurrence after curative pancreaticoduodenectomy of pancreatic head cancer ( χ2=5.833, 9.276, 4.261, P<0.05). Results of multivariate analysis showed that postoperative CA19-9 >37 U/mL was an independent risk factor for early recurrence after curative pancreaticoduodenectomy of pancreatic head cancer ( odd ratio=3.599,95% confidence interval as 1.551-8.347, P<0.05). Conclusion:Postoperative CA19-9>37 U/mL is an independent risk factor for early recurrence after curative pancreaticoduodenectomy of pancreatic head cancer.

The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020) / 中华消化外科杂志

Pancreatic neuroendocrine neoplasms (pNENs) are highly heterogeneous, and the management of pNENs patients can be intractable. To address this challenge, an expert committee was established on behalf of the Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association, which consisted of surgical oncologists, gastroenterologists, medical oncologists, endocrinologists, radiologists, pathologists, and nuclear medicine specialists. By reviewing the important issues regarding the diagnosis and treatment of pNENs, the committee concluded evidence-based statements and recommendations in this article, in order to further improve the management of pNENs patients in China.

Key points of clinical trials of pancreatitis: enlightenment from ESCAPE study / 中华消化外科杂志

The clinical trial is a crucial part of the clinical study. High level medical evidence, getting from the clinical trial, can guide the clinical practice. Compared with pancreatic cancer, the number of clinical trials of pancreatitis is still less as it is a special and complicated disease. The ESCAPE study, initiated by the Dutch pancreatitis research group, was a prospective, multicenter, randomized clinical trial to find the best approach for patients with painful chronic pancreatitis. The results of ESCAPE study were published on the Journal of the American Medical Association in 2020. ESCAPE study is a paradigm for clinical trial of pancreatitis from trial design, study implementation and result analysis. This paper not only focuses on the latest results of ESCAPE study, but also summarizes the key points and problems of clinical trials of pancreatitis. It is extremely urgent to launch clinical trials of pancreatitis widely and canonically, which is helpful to increase the influence of China in the field of pancreas.

New advances in diagnosis and treatment of pancreatic cancer / 中华消化外科杂志

Due to insidious onset,rapid progress,poor curative effect and poor prognosis,pancreatic cancer is known as a high degree of malignity.the incidence of pancreatic cancer and its clinical detection rate have increased in recent years,and it has become one of the malignant diseases endangering health of people.Therefore,the authors review and summarize the recent important research progress in the diagnosis and treatment of pancreatic cancer.

2017 ENETS consensus guidelines: update for the standard of care of pancreatic neuroendocrine tumors / 中华外科杂志

Neuroendocrine tumors(NET) is a rare tumor with high heterogeneity.Pancreatic NET is the most common type in China. European Neuroendocrine Tumor Society(ENETS) has launched the ENETS guidelines since 2006 and published the ENETS standard of care in 2009. With the newly targeted therapies and further research on NET, 2017 new edition of the ENETS standard of care has changed a lot in the diagnosis and treatment of NET. This article explains the update of pancreatic NET in the 2017 edition of the ENETS standard of care, and introduces pancreatic NET from pathology, imaging examination, surgery, systemic therapy, etc., and deepens the understanding of the diagnosis and treatment of pancreatic NET.

The Nedd8-activating enzyme inhibitor MLN4924 suppresses colon cancer cell growth via triggering autophagy

Neddylation is a post-translational protein modification process. MLN4924 is a newly discovered pharmaceutical neddylation inhibitor that suppresses cancer growth with several cancer types. In our study, we first investigated the effect of MLN4924 on colon cancer cells (HCT116 and HT29). MLN4924 significantly inhibited the neddylation of cullin-1 and colon cancer cell growth in a time and dose-dependent manner. MLN4924 induced G2/M cell cycle arrest and apoptosis in HCT116 and HT29 cells. Moreover, MLN4924 also triggered autophagy in HCT116 and HT29 cells via suppressing the PI3K/AKT/mTOR pathway. Inhibiting autophagy by autophagy inhibitor 3-MA or ATG5 knockdown reversed the function of MLN4924 in suppressing colon cancer cell growth and cell death. Interestingly, MLN4924 suppresses colon cell growth in a xenograft model. Together, our finding revealed that blocking neddylation is an attractive colon cancer therapy strategy, and autophagy might act as a novel anti-cancer mechanism for the treatment of colon cancer by MLN4924.

Predictive value of the plasma D-dimer levels on stage and response to chemotherapy of the pancreatic cancer / 中华消化外科杂志

Objective To investigate the predictive value of the plasma D-dimer levels on stage and response to chemotherapy of the pancreatic cancer (PC).Methods The retrospective cross-sectional study was conducted.The clinicopathological data of 212 PC patients who were admitted to the Fudan University Shanghai Cancer Center between December 2016 and May 2017 were collected.Plasma D-dimer levels of 212 patients were measured,and relationship between plasma D-dimer levels and clinicopathological features or response to chemotherapy were analyzed.Observation indicators:(1) relationship between clinicopathological features and positive rate of plasma D-dimer before treatment;(2) relationship between response to chemotherapy and plasma D-dimer levels;(3) follow-up and survival situations.Follow-up using telephone interview was performed to detect survival of patients up to January 2018.Comparisons of count data were analyzed using chi-square test.Measurement data with skewed distribution were described as M (range).Results (1) Relationship between clinicopathological features and positive rate of plasma D-dimer before treatment:positive rate of plasma D-dimer before treatment was respectively 18.37％ (9/49),43.64％ (24/55),53.85％ (28/52),80.36％ (45/56) in patients with stage Ⅰ-Ⅱ A,ⅡB,Ⅲ and Ⅳ of TNM staging and 43.59％(17/39),24.62％(16/65) in patients with low-differentiated tumor and high-and moderate-differentiated tumor,with statistically significantly differences (x2 =41.454,4.051,P＜0.05).(2) Relationship between response to chemotherapy and plasma D-dimer levels:of 212 PC patients,108 received pathological diagnosis by endoscopic ultrasonography or liver puncture,and then underwent 4-6 cycles chemotherapy with gemcitabine.Of 108 patients,response to chemotherapy of 59 patients was partial remission or stable disease,plasma D-dimer level before treatment was increased in 39 patients (28 with reduced plasma D-dimer level after treatment) and normal in 20 patients;response to chemotherapy of 49 patients was progressive disease,plasma D-dimer level before treatment was increased in 34 patients (8 with reduced plasma D-dimer level after treatment) and normal in 15 patients.There was no statistically significant difference in proportion of patients with increased plasma D-dimer level before treatment (x2=0.132,P＞0.05),and there was a statistically significant difference in proportion of patients with reduced plasma D-dimer level after treatment (x2 =16.929,P＜0.05).(3) Follow-up and survival situations:212 patients were followed up for 3.5-12.0 months,with a median time of 7.5 months.During the follow-up,7 patients died and 205 had survival.Conclusion The plasma D-dimer level is significantly associated with TNM staging of the PC,tumor differentiation and response to chemotherapy.

Application value of Braun anastomosis in pancreaticoduodenectomy / 中华消化外科杂志

Objective To investigate the application value of Braun anastomosis in pancreaticoduodenectomy.Methods The retrospective cohort study was conducted.The clinicopathological data of 389patients who underwent pancreaticoduodenectomy in the Fudan University Shanghai Cancer Center from March 2012 to July 2014 were collected.Of 389 patients,235 receiving Braun anastomosis and 154 receiving non-Braun anastomosis were respectively allocated into Braun anastomosis group and non-Braun anastomosis group.All the patients underwent pancreaticoduodenectomy with digestive tract reconstruction using Child method.Patients in the Braun anastomosis group received 5-10 cm Braun anastomosis between input and output end of jejunum,and patients in the non-Braun anastomosis group didn't receive jejunum-jejunum Braun anastomosis after gastrojejunostomy.Observation indicators included:(1) intraoperative situations;(2) postoperative recovery;(3) follow-up.Patients were followed up using outpatient examination and telephone interview up to May 2015.Follow-up included monthly routine blood retest,hepatorenal function retest and urine and stool routine retest,and enhanced CT scan in the epigastric region for every three months to detect recovery of digestive tract function.Measurement data with normal distribution were represented as x±s.Comparison between groups was analyzed using t test,and count data were analyzed using chi-square test.Results (1) Intraoperative situations:389 patients underwent successful pancreaticoduodenectomy.Standard pancreaticoduodenectomy and pyloric-preserving pancreaticoduodenectomy were respectively applied to 205 and 30 patients in the Braun anastomosis group and 137 and 17 patients in the non-Braun anastomosis group,with no statistically significant difference (x2=0.259,P＞0.05).Anastomosis and reconstruction of pancreatic stump:anastomosis of main pancreatic duct and jejunal mucosa,embedded anastomosis of papillary main pancreatic duct and pancreas-stomach anastomosis were detected in 138,89,8 patients in the Braun anastomosis group and 85,60,9 patients in the non-Braun anastomosis group,respectively,with no statistically significant difference (x2 =1.535,P＞ 0.05).Total operation time,pancreasjejunum anastomosis time and volume of intraoperative blood loss were (398.9 ± 61.9) minutes,(20.6 ±3.5) minutes,(401 ± 59) mL in the Braun anastomosis group and (401.3± 59.2) minutes,(20.7± 2.1) minutes,(407± 159)mL in the non-Braun anastomosis group,respectively,with no statistically significant difference (t =-0.380,-0.562,-0.319,P＞0.05).(2) Postoperative recovery:time to initial anal exsufflation,time for fluid diet intake and time of drainage tube removal were (103 ± 28) hours,(77± 25) hours,(12 ± 5) days in the Braun anastomosis group and (102 ± 31) hours,(79 ± 30) hours,(13 ± 6) days in the non-Braun anastomosis group,respectively,with no statistically significant difference (t =0.330,-0.712,-1.783,P＞0.05).Delayed gastric emptying,gastrointestinal hemorrhage,obstruction of afferent loop and pancreatic fistula were detected in 25,3,0,30 patients in the Braun anastomosis group and 27,4,2,23 patients in the non-Braun anastomosis group,respectively,with no statistically significant difference (x2=3.818,0.918,3.068,0.695,P＞0.05).Seventeen patients were combined with delayed gastric emptying and pancreatic fistula,including 8 in the Braun anastomosis group and 9 in the non-Braun anastomosis group,with no statistically significant difference between the 2 groups (x2=1.363,P＞0.05).Patients with postoperative complications were improved by symptomatic and supporting treatment.Duration of hospital stay and treatment expenses were (14±7) days,(73 205±4 538)yuan in the Braun anastomosis group and (22± 11) days,(83 219±5 738) yuan in the non-Braun anastomosis group,with statistically significant differences between the 2 groups (t=-8.767,-19.139,P＜0.05).(3) Follow-up:389 patients were followed up for 6 months,without death.Six and 9 patients in the Braun anastomosis group and non-Braun anastomosis group had regurgitation cholangitis.There was no readmission due to gastrointestinal hemorrhage and digestive tract obstruction,and no signs of hyperglycaemia and intractable diarrhea occurred.Conclusion Braun anastomosis can reduce duration of postoperative hospital stay and treatment expenses.

Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going

Pancreatic ductal adenocarcinoma (PDAC) is among the most devastating human malignancies. The poor clinical outcome in PDAC is partly attributed to a growth-permissive tumor microenvironment. In the PDAC microenvironment, the stroma is characterized by the development of extensive fibrosis, with stromal components outnumbering pancreatic cancer cells. Each of the components within the stroma has a distinct role in conferring chemoresistance to PDAC, and intrinsic chemoresistance has further worsened this pessimistic prognosis. The nucleoside analog gemcitabine (GEM) is usually the recommended first-line chemotherapeutic agent for PDAC patients and is given alone or in combination with other agents. The mechanisms of intrinsic resistance to GEM are an active area of ongoing research. This review highlights the important role the complex structure of stroma in PDAC plays in the intrinsic resistance to GEM and discusses whether antistroma therapy improves the efficacy of GEM. The addition of antistroma therapy combined with GEM is expected to be a novel therapeutic strategy with significant survival benefits for PDAC patients.

Recent advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2016 / 中国癌症杂志

Pancreatic cancer is a highly malignant, fast progressive digestive system neoplasm with poor prognosis, and the incidence has increased significantly in the recent years. The treatment mode of pancreatic cancer has been transformed from surgery-first approach to multidisciplinary approach including surgery, chemotherapy, radiotherapy and other comprehensive treatment modalities, accompanying with significant improvement in clinical efficacy. During the last decade, the molecular mechanism of pancreatic cancer has been explored in depth. Indeed, we had a clearer understanding of the disease, which provides clues for translation of basic research into clinical practice. This review summarized recent high quality studies on pancreatic cancer including pathogenic factor, advances in basic research, and clinical treatment.

The clinical interpretation of modified staging system for pancreatic neuroendocrine tumors / 中国癌症杂志

Pancreatic neuroendocrine tumor is a common pancreatic tumor with high heterogeneity and multiple management modalities. A standard and practical staging system for pancreatic neuroendocrine tumors will be beneficial to clinical management and research. At present, there are two staging systems (ENETS and AJCC). Both of them have shortcomings which limit their clinical application. In addition, the coexistence of two staging systems is confusing to clinicians. We proposed a modified ENETS staging system by keeping the ENETS TNM definition and adopting the AJCC staging definition. The modified staging system can successfully distinguish patients with different prognosis and is helpful in establishing clinical standard. This study has been published in Journal of Clinical Oncology (JCO) and was selected as 2017 Best of JCO: Gastrointestinal edition. This paper was aimed to interpret the modified staging system in clinical practice.

Expression of microtubule-associated protein 2 correlates with better prognosis of pancreatic neuroendocrine tumors / 中国肿瘤临床

Objective: To determine whether microtubule-associated protein 2 (MAP2) and microtubule-associated protein 1B (MAP1B) could be prognostic biomarkers for patients with pancreatic neuroendocrine tumors (PNETs). Methods:With immunohisto-chemical staining, the expressions of MAP2 and MAP1B were examined in 193 and 120 primary tumors and peritumoral tissues, re-spectively. Then, the relationship between the expression of each protein and clinicopathological characteristics, including prognosis was analyzed. Results:MAP2 and MAP1B were expressed in 88 of 193 (45.6%) and 77 of 120 (64.2%) tumors, respectively. The expres-sion of MAP2 was significantly associated with the favorable overall survival of patients with PNETs (P=0.012). Moreover, MAP2 expres-sion was associated with the improved overall survival in a subset of patients with stageⅡand stageⅢtumors (P=0.017). The MAP1B expression did not correlate with other clinicopathological features and prognosis. Conclusion:MAP2 could be a novel, independent prognostcbiomarker for PNETs.

Analysis of the advances in pancreatic cancer research from 2017 annual meeting of Chinese Society of Clinical Oncology / 中华消化外科杂志

Pancreatic cancer is a highly malignant,fast progressive digestive system neoplasm with poor prognosis,and the incidence has increased significantly in recent years.With deepening of the molecular mechanism of pancreatic cancer,researchers indeed have a clearer understanding of the disease,which provides clues for translation of basic research into clinical practice.The 2017 annual meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Xiamen on September 26th to 30th.In this paper,authors selected and reviewed advances in pancreatic cancer research on surgical treatment,chemotherapy,radiotherapy,targeted therapy and immnunotherapy on pancreatic cancer from 2017 CSCO,in order to provide new clues for optimization of diagnosis and treatment of pancreatic cancer.

Application value of Braun anastomosis in pancreaticoduodenectomy / 中华消化外科杂志

Objective To investigate the application value of Braun anastomosis in pancreaticoduodenectomy.Methods The retrospective cohort study was conducted.The clinicopathological data of 389patients who underwent pancreaticoduodenectomy in the Fudan University Shanghai Cancer Center from March 2012 to July 2014 were collected.Of 389 patients,235 receiving Braun anastomosis and 154 receiving non-Braun anastomosis were respectively allocated into Braun anastomosis group and non-Braun anastomosis group.All the patients underwent pancreaticoduodenectomy with digestive tract reconstruction using Child method.Patients in the Braun anastomosis group received 5-10 cm Braun anastomosis between input and output end of jejunum,and patients in the non-Braun anastomosis group didn't receive jejunum-jejunum Braun anastomosis after gastrojejunostomy.Observation indicators included:(1) intraoperative situations;(2) postoperative recovery;(3) follow-up.Patients were followed up using outpatient examination and telephone interview up to May 2015.Follow-up included monthly routine blood retest,hepatorenal function retest and urine and stool routine retest,and enhanced CT scan in the epigastric region for every three months to detect recovery of digestive tract function.Measurement data with normal distribution were represented as x±s.Comparison between groups was analyzed using t test,and count data were analyzed using chi-square test.Results (1) Intraoperative situations:389 patients underwent successful pancreaticoduodenectomy.Standard pancreaticoduodenectomy and pyloric-preserving pancreaticoduodenectomy were respectively applied to 205 and 30 patients in the Braun anastomosis group and 137 and 17 patients in the non-Braun anastomosis group,with no statistically significant difference (x2=0.259,P＞0.05).Anastomosis and reconstruction of pancreatic stump:anastomosis of main pancreatic duct and jejunal mucosa,embedded anastomosis of papillary main pancreatic duct and pancreas-stomach anastomosis were detected in 138,89,8 patients in the Braun anastomosis group and 85,60,9 patients in the non-Braun anastomosis group,respectively,with no statistically significant difference (x2 =1.535,P＞ 0.05).Total operation time,pancreasjejunum anastomosis time and volume of intraoperative blood loss were (398.9 ± 61.9) minutes,(20.6 ±3.5) minutes,(401 ± 59) mL in the Braun anastomosis group and (401.3± 59.2) minutes,(20.7± 2.1) minutes,(407± 159)mL in the non-Braun anastomosis group,respectively,with no statistically significant difference (t =-0.380,-0.562,-0.319,P＞0.05).(2) Postoperative recovery:time to initial anal exsufflation,time for fluid diet intake and time of drainage tube removal were (103 ± 28) hours,(77± 25) hours,(12 ± 5) days in the Braun anastomosis group and (102 ± 31) hours,(79 ± 30) hours,(13 ± 6) days in the non-Braun anastomosis group,respectively,with no statistically significant difference (t =0.330,-0.712,-1.783,P＞0.05).Delayed gastric emptying,gastrointestinal hemorrhage,obstruction of afferent loop and pancreatic fistula were detected in 25,3,0,30 patients in the Braun anastomosis group and 27,4,2,23 patients in the non-Braun anastomosis group,respectively,with no statistically significant difference (x2=3.818,0.918,3.068,0.695,P＞0.05).Seventeen patients were combined with delayed gastric emptying and pancreatic fistula,including 8 in the Braun anastomosis group and 9 in the non-Braun anastomosis group,with no statistically significant difference between the 2 groups (x2=1.363,P＞0.05).Patients with postoperative complications were improved by symptomatic and supporting treatment.Duration of hospital stay and treatment expenses were (14±7) days,(73 205±4 538)yuan in the Braun anastomosis group and (22± 11) days,(83 219±5 738) yuan in the non-Braun anastomosis group,with statistically significant differences between the 2 groups (t=-8.767,-19.139,P＜0.05).(3) Follow-up:389 patients were followed up for 6 months,without death.Six and 9 patients in the Braun anastomosis group and non-Braun anastomosis group had regurgitation cholangitis.There was no readmission due to gastrointestinal hemorrhage and digestive tract obstruction,and no signs of hyperglycaemia and intractable diarrhea occurred.Conclusion Braun anastomosis can reduce duration of postoperative hospital stay and treatment expenses.

Clinicopathological characteristics and prognosis analysis of colorectal neuroendocrine neoplasms based on the data from domestic six medical centers / 中华胃肠外科杂志

<p><b>OBJECTIVE</b>To investigate the clinicopathological characteristics and their relationship with prognosis of colorectal neuroendocrine neoplasms (NEN).</p><p><b>METHODS</b>Medical records of 329 patients with colorectal NEN between June 2001 and July 2016 from 6 large scale centers in China were reviewed to investigate the clinicopathological characteristics and their relationship with prognosis of colorectal NEN.</p><p><b>RESULTS</b>(1) Colonic NEN: A total of 41 patients with colonic NEN were enrolled from The First Affiliated Hospital of Sun Yat-sen University(n=11), Sun Yat-sen University Cancer Center (n=15), Guangdong General Hospital (n=10), Sun Yet-san Memorial Hospital of Sun Yat-sen University (n=3) and Fudan University Shanghai Cancer Center (n=2). 41 cases, including 20 males and 21 females with a mean age of (58.7±4.7) years. Twenty-three colonic NEN originated in hindgut (23/41, 56.1%), and 20 patients were stage IIII( (20/41, 48.8%). Nine cases (22.0%) were neuroendocrine tumor(NET), 25(61.0%) were neuroendocrine carcinoma (NEC) and 7(17.1%) were mixed adenoendocrine carcinoma (MANEC). Six cases (14.6%) were G1 grade, 3(7.3%) were G2 grade and 32(78.1%) were G3 grade. Ulcerative or cauliflower-like tumors were the most common appearance under endoscopy (both 9/41, 22.0%). Thirty-three patients (80.5%) underwent surgery. During follow-up, 19 cases died and the 3-year survival rate was 46.1%. Multivariate analysis revealed that stage IIII( was an independent risk factor of poor prognosis (HR=3.871, 95%CI:1.342 to 11.167, P=0.012) in colonic NEN patients. (2) Rectal NEN: A total of 288 patients with rectal NEN were enrolled from The First Affiliated Hospital of Sun Yat-sen University(n=130), Nanfang Hospital of Southern Medical University (n=115) and Fudan University Shanghai Cancer Center (n=43). Two hundred and eighty-eight cases, including 181 males and 107 females with a mean age of (47.7±1.5) years. One hundred and ninety-seven patients were stage I((197/288, 68.4%). Of 288 rectal NEN cases, 267(92.7%) were NET, 20(7.0%) were NEC and 1(0.3%) was MANEC; 214(74.3%) were G1 grade, 53(18.4%) were G2 grade and 21(7.3%) were G3 grade. Submucosal tumor was the most common appearance under endoscopy(164/288, 56.9%). Most of the rectal NET G1/G2 tumors were submucosal(146/214, 68.2%;18/53,34.0% respectively) while most of G3 tumors were cauliflower-like (14/21,66.7%). A total of 175 patients (60.8%) underwent endoscopic therapy, while 96 patients(33.3%) underwent surgery. During follow-up, 12 cases died and 3-year survival rate was 94.0%. Multivariate analysis revealed that poor differentiation as NEC or MANEC(HR=8.919, 95% CI:1.911 to 41.637, P=0.005) and stage III( to IIII((HR=10.304, 95%CI:1.772 to 59.916, P=0.009) were independent risk factors of poor prognosis in rectal NEN patients.</p><p><b>CONCLUSIONS</b>The clinicopathological manifestations of rectal NEN and colonic NEN are quite different. Rectal NEN are more common with better differentiation and has better prognosis than colonic NEN.</p>

Clinical application value of lymph node ratio in pancreatic cancer / 中华消化外科杂志

Lymphatic metastasis is an important prognostic factor for pancreatic cancer.However,lymphatic metastatic status (N0 or N1) can not reflect the degree of lymphatic metastasis.Lymph node ratio,which is defined as the number of positive lymph nodes divided by total examined lymph nodes,can reflect the degree of lymph metastatic metastasis and give consideration to examined lymph nodes.Lymph node ratio is superior to lymph metastatic status in staging,guiding treatment,and predicting prognosis.However,currently,lymph node ratio cannot replace lymph metastatic status for the undetermined minimum number of examined lymph nodes and cut-off value.Further evidence is needed to prove its clinical value.

The influence of E-cadherin/β-catenin on the glycolysis effect in PANC-1 cells / 中国癌症杂志

Background and purpose:Lower expression of E-cadherin is associated with metastasis of cancer cells, however, the correlation between E-cadherin and glucose metabolism has seldom been reported. This article studied the correlation between E-cadherin and glycolysis effect in PANC-1 cells.Methods:Through treatment of transforming growth factor β (TGF-β) in PANC-1 cells to decrease E-cadherin expression, knock-down the gene of E-cadherin interaction protein β-catenin, and overexpressing of E-cadherin, the effects of E-cadherin on the glucose uptake and lactate production ability and on the expression of key glycolytic genes were assessed.Results:E-cadherin negatively regulated the glycolytic effect of PANC-1 cells by inhibiting glucose uptake and lactate production (P<0.05). Moreover, E-cadherin interacting partner β-catenin signiifcantly promoted glucose metabolism transformation in PANC-1 cells (P<0.05). Moreover, key glycolysis regulator sirtuin 3 (SIRT3) could lower E-cadherin expression.Conclusion:Lower expression of E-cadherin induced the transformation of glucose metabolism transformation in PANC-1 cells and manipulation of E-cadherin expression level could change the glycolysis effect. Moreover, through maneuver glycolysis process could inhibit high metastatic potential of pancreatic cancer cells.

The value of ultrasound in detecting solid pseudopapillary tumor of the pancreas / 中国癌症杂志

Background and purpose:Ultrasound is a regular screening method of solid pseudopapillary tumor of the pancreas (SPTP). This study was to summarize the diagnostic value of ultrasound to SPTP.Methods:Clinical and ultrasound data of 62 SPTP cases in Fudan University Shanghai Cancer Center were retrospectively collected and analyzed.Results:Five cases of SPTP were undetected by ultrasound in the group. The features of ultrasound including: large mass located at the body and tail of the pancreas, clear boundary and regular shape, low ultrasound with uneven signal, or low signal mixed with no signal. A few cases have calciifcation and blood signal. Most of the cases presented no dilation of main pancreatic duct and bile duct and regional lymph nodes enlargement. Conclusion:Ultrasound can be used to detect SPTP which has special ultrasound signal features.

Standard in the clinical management of the lymph metastasis in pancreatic cancer / 中国癌症杂志

Lymph metastasis has great impact on the prognosis of pancreatic cancer patients, which can relfect the biological and invasive potential of pancreatic cancer. However, currently, there is no standard in the clinical management of the lymph metastasis in pancreatic cancer. In this report, we will discuss and summarize the followings:lymph metastatic rate and its impact on prognosis, the rule of lymph metastasis, sentinel lymph node, intra-operative lymph nodes mapping, TNM staging, regional lymph nodes resection, number of lymph nodes examined, lymph node ratio, guiding adjuvant treatments, lymphatic targeted therapy.